AKTX
Price
$8.23
Change
-$0.53 (-6.05%)
Updated
Oct 22 closing price
Capitalization
16.02M
21 days until earnings call
Intraday BUY SELL Signals
QURE
Price
$23.11
Change
+$0.42 (+1.85%)
Updated
Oct 22 closing price
Capitalization
1.6B
18 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

AKTX vs QURE

AKTX vs QURE Comparison Chart in %
View a ticker or compare two or three
VS
AKTX vs. QURE commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AKTX is a Buy and QURE is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for AKTX with price predictions
Oct 22, 2026

AKTX's RSI Oscillator ascending out of oversold territory

The RSI Indicator for AKTX moved out of oversold territory on October 15, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 39 similar instances when the indicator left oversold territory. In 36 of the 39 cases the stock moved higher. This puts the odds of a move higher at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for AKTX just turned positive on October 20, 2026. Looking at past instances where AKTX's MACD turned positive, the stock continued to rise in 38 of 49 cases over the following month. The odds of a continued upward trend are 78%.

The 50-day moving average for AKTX moved above the 200-day moving average on October 21, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a +9.17% 3-day Advance, the price is estimated to grow further. Considering data from situations where AKTX advanced for three days, in 153 of 201 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.

AKTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 39 of 41 cases where AKTX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.

The Momentum Indicator moved below the 0 level on October 22, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AKTX as a result. In 96 of 100 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

AKTX moved below its 50-day moving average on October 21, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for AKTX crossed bearishly below the 50-day moving average on October 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 10 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AKTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for AKTX entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 4 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating steady price growth. AKTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 98 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.862) is normal, around the industry mean (2.973). AKTX's P/E Ratio (95.710) is considerably higher than the industry average of (-1.705). Projected Growth (PEG Ratio) (1.890) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AKTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for QURE with price predictions
Oct 22, 2026

QURE in upward trend: price expected to rise as it breaks its lower Bollinger Band on September 29, 2026

QURE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 27 of 33 cases where QURE's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 82%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where QURE's RSI Indicator exited the oversold zone, 26 of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.

The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on QURE as a result. In 67 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.

The Moving Average Convergence Divergence (MACD) for QURE just turned positive on October 16, 2026. Looking at past instances where QURE's MACD turned positive, the stock continued to rise in 33 of 41 cases over the following month. The odds of a continued upward trend are 80%.

Following a +4.29% 3-day Advance, the price is estimated to grow further. Considering data from situations where QURE advanced for three days, in 206 of 267 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

QURE moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for QURE crossed bearishly below the 50-day moving average on September 18, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 17 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where QURE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.

The Aroon Indicator for QURE entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 41 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.947) is normal, around the industry mean (2.973). P/E Ratio (-5.692) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.020) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (142.857) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. QURE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. QURE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
AKTX vs QURE: Fundamental Ratings
AKTX
QURE
OUTLOOK RATING
1..100
42
VALUATION
overvalued / fair valued / undervalued
1..100
98
Overvalued
41
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9999
PRICE GROWTH RATING
1..100
5965
P/E GROWTH RATING
1..100
412
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

QURE's Valuation (41) in the Biotechnology industry is somewhat better than the same rating for AKTX (98) in the Pharmaceuticals Major industry. This means that QURE’s stock grew somewhat faster than AKTX’s over the last 12 months.

QURE's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as AKTX (100) in the Pharmaceuticals Major industry. This means that QURE’s stock grew similarly to AKTX’s over the last 12 months.

QURE's SMR Rating (99) in the Biotechnology industry is in the same range as AKTX (99) in the Pharmaceuticals Major industry. This means that QURE’s stock grew similarly to AKTX’s over the last 12 months.

AKTX's Price Growth Rating (59) in the Pharmaceuticals Major industry is in the same range as QURE (65) in the Biotechnology industry. This means that AKTX’s stock grew similarly to QURE’s over the last 12 months.

AKTX's P/E Growth Rating (4) in the Pharmaceuticals Major industry is in the same range as QURE (12) in the Biotechnology industry. This means that AKTX’s stock grew similarly to QURE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AKTXQURE
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
74%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
81%
MACD
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
80%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
78%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
88%
Advances
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 3 days ago
77%
Declines
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 9 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
89%
Bullish Trend 1 day ago
82%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
88%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (AKTX: $8.76 vs. QURE: $23.11)
Brand notoriety: AKTX and QURE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AKTX: 32% vs. QURE: 73%
Market capitalization -- AKTX: $16.02M vs. QURE: $1.6B
AKTX [@Biotechnology] is valued at $16.02M. QURE’s [@Biotechnology] market capitalization is $1.6B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $135.64B. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AKTX’s FA Score shows that 1 FA rating(s) are green while QURE’s FA Score has 1 green FA rating(s).

  • AKTX’s FA Score: 1 green, 4 red.
  • QURE’s FA Score: 1 green, 4 red.
According to our system of comparison, QURE is a better buy in the long-term than AKTX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AKTX’s TA Score shows that 6 TA indicator(s) are bullish while QURE’s TA Score has 4 bullish TA indicator(s).

  • AKTX’s TA Score: 6 bullish, 5 bearish.
  • QURE’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, AKTX is a better buy in the short-term than QURE.

Price Growth

AKTX (@Biotechnology) experienced а +20.66% price change this week, while QURE (@Biotechnology) price change was +2.62% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.

Reported Earning Dates

AKTX is expected to report earnings on Nov 12, 2026.

QURE is expected to report earnings on Nov 09, 2026.

Industries' Descriptions

@Biotechnology (-1.10% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
AKTX
Daily Signal:
Gain/Loss:
QURE
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

AKTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, AKTX has been loosely correlated with CNTN. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if AKTX jumps, then CNTN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AKTX
1D Price
Change %
AKTX100%
-6.05%
CNTN - AKTX
34%
Loosely correlated
-3.63%
KPRX - AKTX
30%
Poorly correlated
-2.09%
QURE - AKTX
29%
Poorly correlated
+1.85%
GOVX - AKTX
27%
Poorly correlated
-8.40%
CVKD - AKTX
25%
Poorly correlated
-4.90%
More

QURE and

Correlation & Price change

A.I.dvisor indicates that over the last year, QURE has been loosely correlated with CNTN. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if QURE jumps, then CNTN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To QURE
1D Price
Change %
QURE100%
+1.85%
CNTN - QURE
49%
Loosely correlated
-3.63%
AXON - QURE
42%
Loosely correlated
+2.98%
MLTX - QURE
37%
Loosely correlated
+15.87%
SNGX - QURE
36%
Loosely correlated
+0.30%
STOK - QURE
34%
Loosely correlated
+0.08%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PEGA36.651.47
+4.18%
Pegasystems Inc
DOLE13.520.41
+3.13%
Dole plc
ATHR2.540.03
+1.20%
Aether Holdings Inc
HRZN4.00-0.04
-0.99%
Horizon Technology Finance Corp
CEG255.21-15.53
-5.74%
Constellation Energy Corp